Listen to this article · 8 min listen

Not all clinical AI performance claims are built the same. If you’re a VC doing tech DD in life sciences or digital health, your ability to tell marketing fluff from validated clinical reality is everything. This is a breakdown of how to vet diagnostic accuracy claims, giving you a framework to pick apart the evidence behind the next AI health company you look at.

Why Self-Reported Accuracy is a Red Flag

In AI health, the whole game is diagnostic accuracy. It’s the competitive edge everyone is chasing. But just taking a company’s word on their performance metrics is a huge mistake. You can’t get to commercial success in the US without FDA clearance, and you can’t get clearance without solid clinical evidence. It’s that simple. If you don’t get a good look at the data behind those sensitivity and specificity claims, you could end up backing a company that crashes and burns at the FDA or one that doctors just won’t use because its real-world performance is a mystery. The FDA’s Center for Devices and Radiological Health (CDRH) database is where the truth lives. It’s where you can see what AI health companies actually did for their clinical studies, their patient cohorts, and what performance they proved for devices seeking 510(k) clearance or a De Novo classification. Reading these summaries, not the company’s PR, is step one of any serious tech DD.

Deconstructing Validation: Aidoc’s Playbook

Aidoc is a big name in AI health, and they’ve gotten good at the FDA regulatory game, with 31 510(k) clearances as of May 2026. Looking at their public FDA decision summaries, their strategy is clear: get clearance using retrospective clinical studies. This approach gets them to market much faster than a full-blown prospective trial because they can just use existing, often de-identified, patient data. Digging into Aidoc’s 510(k) summaries for their various imaging algorithms shows the same pattern again and again:

  • Retrospective Data: Their clinical trials are almost always run on large, archived sets of medical images, which makes data collection and analysis super fast.
  • Predicate Device Equivalence: The 510(k) path is all about proving you’re “substantially equivalent” to something already on the market. Aidoc’s filings typically show their AI performing as well as a human expert or another established method on these old datasets.
  • Performance Metrics: The FDA summaries always report sensitivity and specificity, which are calculated from these retrospective runs. For instance, a filing might show the AI detecting acute intracranial hemorrhage with 92% sensitivity and 95% specificity on a set of 500 CT scans Example FDA 510(k) summary for Aidoc intracranial hemorrhage detection.

Retrospective studies are an efficient way to get an initial green light from the FDA, but as a VC, you have to ask more questions. How diverse was that patient cohort? Were the images from one hospital or twenty? Did the data include a realistic mix of ethnicities, ages, and comorbidities that you’d see in actual clinical practice? Even a huge dataset is a problem if it’s too narrow, the algorithm will start to fail (this is called algorithmic drift) when it gets deployed in a different hospital system.

PathAI’s Multi-Center Validation Approach

PathAI, a major player in AI-powered pathology, has taken a different route for many of its algorithms, relying on peer-reviewed, multi-center trials for validation. It’s a harder, more expensive path, but it produces much stronger evidence of how the algorithm will generalize and perform in the wild. PathAI proves its pathology algorithms work with rigorous studies, often prospective or very large-scale retrospective ones, that get published in top-tier medical journals. These studies usually involve:

  • Multi-center Collaboration: They collect data from a bunch of different clinical sites, which immediately deals with the big questions around patient diversity and variations between hospitals. This gives you confidence the algorithm will actually work in different healthcare systems with different kinds of patients.
  • Peer-Reviewed Publications: Getting published means the results survived a tough peer-review process, which is another layer of scientific vetting on top of what the FDA requires. PathAI has a long list of these, with 20 clinical trials in oncology and 10 in MASH, which sends a powerful signal that they’re serious about clinical evidence PathAI peer-reviewed publications list.
  • Clinical Endpoints: These studies look past simple sensitivity and specificity and get into what really matters for a clinic: does the AI agree with expert pathologists, does it speed up diagnosis, or does it actually change patient outcomes? This gives a much fuller picture of the tool’s real-world utility.

PathAI’s focus on multi-center, peer-reviewed evidence shows they’re committed to proving their accuracy is reproducible across different clinical environments. For an investor, this distinction is everything because reproducible accuracy is what leads to broad clinical adoption and long-term commercial success, not a one-off study in a perfect lab environment.

Key Questions for Founders: Get Past the Pitch Deck

As a VC, you need a system for breaking down these clinical performance claims during tech DD. When you’re looking at an AI health company that’s bragging about its diagnostic accuracy, you need to be ready with some sharp questions for the founders:

  1. Patient Cohort Diversity: “Walk me through the demographics and clinical details of your validation cohorts. Was this a single-site study or multi-site? How did you make sure your training and validation data reflects the real-world population you’re selling to?” If the data isn’t diverse, the algorithm will be biased and its addressable market shrinks. Period.
  2. Retrospective vs. Prospective Data: “What’s the split between your retrospective and prospective data? If it’s mostly retrospective, what did you do to control for the biases in that historical data, and what’s your roadmap for prospective validation?” Retrospective studies can get you an initial FDA clearance, but prospective data is what really proves the tech works in the real world.
  3. Data Labeling and Annotation: “Who did the ground truth labeling for your data? What was their expertise? Did you measure inter-rater reliability, and how did you handle it when your experts disagreed?” The quality of your ground truth is the ceiling for the quality of your performance metrics. Garbage in, garbage out.
  4. Generalizability and External Validation: “What have you done for external validation, outside your main studies? Show me evidence of your algorithm’s performance on a completely independent dataset from a different hospital or health system.” This is the real test of whether the AI is solid and can be used widely.
  5. Algorithmic Drift Mitigation: “How are you monitoring for performance degradation after deployment? What’s your process for updating and re-validating the model once it’s in the wild?” The FDA is all over Predetermined Change Control Plans (PCCPs) now, which tells you how seriously they take the need to manage how these SaMD models change and evolve.

Pushing on these questions gets you past the marketing numbers and into the actual rigor (or lack of it) behind the AI’s stated performance. This kind of deep dive is how you actually de-risk the investment. It separates companies with a real, defensible clinical moat from those that just have a good pitch deck.

Methodology and Source Note

The analysis here comes from digging through public FDA 510(k) summary documents and peer-reviewed medical journal publications. These are the ground-truth documents that show you exactly how these AI companies run their trials and frame their results for regulators and scientists. This framework is about helping you figure out which AI health companies have real clinical performance and which are just momentum plays. FDA 510(k) database search

Frequently Asked Questions

What is the primary method for validating diagnostic accuracy claims in AI health companies seeking regulatory clearance?

The primary method involves scrutinizing FDA Center for Devices and Radiological Health (CDRH) database summaries. These summaries disclose critical details of clinical studies, patient cohorts, and performance metrics for devices seeking 510(k) clearance or De Novo classification, providing robust evidence beyond self-reported metrics.

How do companies like Aidoc typically achieve FDA 510(k) clearance for their AI algorithms?

Aidoc primarily achieves 510(k) clearance through retrospective clinical studies. These studies leverage large, archived datasets of medical images and demonstrate substantial equivalence to a legally marketed predicate device, often comparing AI performance to human expert reads on these datasets.

What are the potential limitations of relying solely on retrospective studies for AI algorithm validation?

While efficient for initial regulatory clearance, retrospective studies can have limitations regarding patient cohort diversity. If the dataset is narrow or homogenous, it may not represent real-world clinical practice, potentially leading to algorithmic drift when deployed in diverse clinical settings.

How does PathAI’s validation approach differ from Aidoc’s, and what advantages does it offer?

PathAI emphasizes multi-center, peer-reviewed trials, often prospective or large-scale retrospective studies, published in high-impact medical journals. This approach offers advantages such as inherent patient cohort diversity from multiple clinical sites, additional scientific scrutiny through peer review, and often investigates broader clinical endpoints beyond basic sensitivity and specificity, demonstrating reproducible accuracy across varied clinical contexts.